戊聚糖多硫酸酯相关黄斑病变患者停药不同时间后的两年结局
这项前瞻性队列研究评估了12例(23眼)戊聚糖多硫酸酯相关黄斑病变患者停药后2年的自然病程,发现即使停药,功能和结构缺陷仍继续进展,表现为微视野平均阈值下降和中心凹下脉络膜厚度无显著变化,但黄斑区完全性视网膜色素上皮和 outer retinal atrophy(cRORA)有所扩大。
要点
- 停药后2年ETDRS最佳矫正视力中位下降3个字母(P=0.08),4眼(17.4%)下降≥15个字母且均伴cRORA进展。
- 微视野平均阈值中位下降3.5 dB(P=0.001),阈值降低百分比中位为32.5%(P=0.004)。
- 基线无萎缩的2眼(8.7%)新发cRORA,基线有cRORA的9眼(39%)线性增长速率中位为0.23 mm/y。
核心结论
- 作者认为,戊聚糖多硫酸酯相关黄斑病变患者停药后功能和结构缺陷仍继续进展。
- 作者指出需要额外研究来确定这些发现能否推广至其他戊聚糖多硫酸酯相关黄斑病变患者,以及更长随访能否确定后续病程。
研究设计与样本
- 这项队列研究前瞻性评估了戊聚糖多硫酸酯相关黄斑病变患者的自然病程。
- 参与者在埃默里眼科中心就诊,于2018年12月1日至2019年12月1日入组,数据收集至2021年11月30日。
- 共纳入12例参与者(23眼),其中11例(91.7%)为女性(1例[8.3%]为男性),11例(91.7%)为白人(1例[8.3%]为黑人),入组时中位(IQR)年龄为58(47-64)岁。
- 从停用戊聚糖多硫酸酯到初次就诊的中位(IQR)时间为0.6(0.4-1.9)年。
主要发现
- 基线ETDRS最佳矫正视力字母评分中位为83(Snellen等效20/20)(IQR,80-86.5[20/25-20/20]),2年变化中位为-3(IQR,-6至-0.5;P=0.08)。
- 4眼(17.4%)字母评分下降≥15,均与进展性cRORA相关。
- 微视野平均阈值变化中位为-3.5 dB(IQR,-4.1至-2.5 dB;P=0.001),阈值降低百分比中位为32.5%(IQR,20.3%-52.8%;P=0.004)。
- 基线时9眼(39%)存在黄斑cRORA,线性化增长速率中位为0.23 mm/y(IQR,0.22-0.25 mm/y);基线无萎缩的2眼(8.7%)新发cRORA。
- 基线黄斑中心子区域厚度中位为284 μm(IQR,253-291 μm),2年变化中位为-5 μm(IQR,-13至0.5 μm;P=0.0497);中心凹下脉络膜厚度2年变化中位为1 μm(IQR,-18至16 μm;P=0.91)。
局限性
- 原文指出需要额外研究来确定这些发现能否推广至其他戊聚糖多硫酸酯相关黄斑病变患者。
- 原文指出需要额外研究来确定更长随访能否确定后续病程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prior retrospective studies have provided limited evidence on disease progression following drug cessation in patients with maculopathy associated with pentosan polysulfate (PPS). OBJECTIVE: To evaluate the 2-year evolution of maculopathy associated with PPS use after drug cessation. DESIGN, SETTING, AND PARTICIPANTS: This cohort study prospectively evaluated the natural history of patients with maculopathy associated with PPS use. Participants seen at the Emory Eye Center were enrolled between December 1, 2018, and December 1, 2019, and data were collected through November 30, 2021. MAIN OUTCOMES AND MEASURES: The main outcomes were changes in visual function and structure. Visual function was assessed annually with refraction and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA), mesopic microperimetry, and dark adaptometry. Structural outcomes included presence and extent of complete retinal pigment epithelium and outer retinal atrophy (cRORA), macular central subfield thickness (CST), and subfoveal choroidal thickness (SFCT). RESULTS: Of the 12 participants (23 eyes), 11 (91.7%) were female (1 [8.3%] male), 11 (91.7%) were White (1 [8.3%] Black), and median (IQR) age at enrollment was 58 (47-64) years. Median (IQR) time from PPS discontinuation to initial visit was 0.6 (0.4-1.9) years. Median baseline ETDRS BCVA letter score was 83 (Snellen equivalent, 20/20) (IQR, 80-86.5 [20/25-20/20]), with a median 2-year change of -3 (IQR, -6 to -0.5; P = .08). Four eyes (17.4%) had a letter score decline of 15 or more, all associated with progressive cRORA. Median change in microperimetry average threshold was -3.5 dB (IQR, -4.1 to -2.5 dB; P = .001), and percent reduced threshold was 32.5% (IQR, 20.3%-52.8%; P = .004). Nine eyes (39%) had macular cRORA at baseline, with a median linearized growth rate of 0.23 mm/y (IQR, 0.22-0.25 mm/y). Two eyes (8.7%) without atrophy at baseline developed new-onset cRORA. Median baseline CST was 284 μm (IQR, 253-291 μm), with a median 2-year change of -5 μm (IQR, -13 to 0.5 μm; P = .0497). Median 2-year change in SFCT was 1 μm (IQR, -18 to 16 μm; P = .91). CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that functional and structural deficits continue to progress in PPS-associated maculopathy even after drug cessation. Additional study is needed to determine whether these findings can be generalized to other patients with PPS-associated maculopathy and whether longer follow-up could determine subsequent disease course.
引用
- Jung EH, Lindeke-Myers A, Jain N, et al. Two-Year Outcomes After Variable Duration of Drug Cessation in Patients With Maculopathy Associated With Pentosan Polysulfate Use. JAMA Ophthalmol. 2023. PMID: 36729449. doi:10.1001/jamaophthalmol.2022.6093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。